Suggested remit: To appraise the clinical and cost effectiveness of difelikefalin within its marketing authorisation for treating pruritus associated with chronic kidney disease in adults having haemodialysis.
Status Awaiting development
Decision None selected
Process STA 2018
ID number 3890

Provisional Schedule

Expected publication 26 April 2023

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
17 November 2021 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early June 2022 when we will write to consultees and commentators about how they can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
21 April 2021 - 20 May 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual